Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
higher as short-sellers considered what to do after the company's share price tripled in just three weeks this year. Trading volume reached 93.5 million shares, about 357% above its three-month average of 20.5 million shares. ImmunityBio IPO'd in 2015 and has fallen 80% since going public. The S&P 500 gained 1.16% to finish Wednesday at 6,875, while the Nasdaq Composite added 1.18% to close at 23,225. Within biotechnology, peers Nkarta closed at $2.2 (+7.84%) and Allogene Therapeutics ended at $1.6 (+1.91%), underscoring ongoing interest in higher-risk drug developers. ImmunityBio's incredible run continued today as short-sellers considered closing their positions in the stock following a tremendous batch of news over the last two weeks. Today's 7% share price increase doesn't really tie to any specific news, but likely stems from a certain amount of these short-sellers covering their positions following recent positive developments. Bloomberg reports that short-sellers now face
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewswire
- ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free TherapyBusiness Wire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/26/26 - Form 8-K
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- IBRX's page on the SEC website